All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche, and Syndax, and supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML?
Featured
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
This educational resource is independently supported by Jazz Pharmaceuticals. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consensus Classification (ICC) of AML on diagnosis and treatment of high-risk acute myeloid leukemia (HR AML)?
The impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of HR AML
Listen to this interview as a podcast:
The impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of HR AML
In this interview, Roboz walks through the changes in the classification criteria for AML over the last 50 years, highlighting the implications of these changes and the lack of consensus on the diagnosis and management strategies for patients. Roboz goes on to discuss both classification and prognostic risk stratification tools to aid in the development of management strategies, including in HR AML, and concludes by highlighting the importance of considering patient preferences and health when making clinical decisions.
Key points and learnings:
-
In the 5th WHO classification, the diagnosis of AML typically requires ≥20% blasts in the bone marrow or peripheral blood. However, there are specific genetic abnormalities which can indicate AML regardless of the blast percentage.1
-
-
As a result, challenges exist in determining treatment intensity in patients with lower blast counts.
-
-
The 5th WHO and the ICC now distinguish AML from related myeloid neoplasms, such as myelodysplastic syndromes (MDS)/AML, and this has led to confusion among patients due to lack of definitive boundaries for disease diagnosis.
-
The latest WHO classification places a stronger emphasis on genetic abnormalities, recognizing them as primary drivers in AML classification.
-
-
AML with mutated TP53 is recognized as a distinct category in the ICC but not in the WHO classification.
-
-
The former category of AML with myelodysplasia-related changes (AML-MRC) is replaced with AML myelodysplasia-related (AML-MR) in the WHO classification and separated into two categories in the ICC; AML with MR gene mutations and AML with MR cytogenetic abnormalities.
-
-
Both classifications now include mutation-based diagnostic criteria, potentially broadening the number of patients included in this category compared with the previous classification.1
-
-
There are, however, some differences, for instance mutations in RUNX1 fall under AML with MR gene mutations in the ICC, but are not diagnostically defining in the WHO classification.
-
The ICC eliminates the previous standalone category of therapy-related AML and instead includes therapy-related as a diagnostic qualifier that can be applied to other AML subgroups.2
-
The differences between the two classification systems have resulted in pathologists reporting both the ICC and WHO classifications for individual patients.
-
The median age for patients with AML is 67 years,3 and many of these older patients are now treated with a non-intensive regimen of a hypomethylating agent plus venetoclax.
-
-
Not all risk stratification tools can correctly stratify these patients, meaning that outcomes are not necessarily determined by AML biology, but depend substantially on what treatments are available.
-
-
It is vital to consider the patient as an individual when determining classification and treatment.
-
-
Overall health status and patient preferences are key in determining treatment in addition to pathology data.
-
7 votes - 40 days left
This educational resource is independently supported by Jazz Pharmaceuticals. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
- Lee C, Kim H, Kwon J, et al. Implications of the 5th edition of the World Health Organization Classification and International Consensus Classification of myeloid neoplasm in myelodysplastic syndrome with excess blasts and acute myeloid leukemia. Ann Lab Med. 2023;43(5):503-507. DOI: 10.3343/alm.2023.43.5.503
- Attardi E, Savi A, Borsellino B, et al. Unraveling the impact of 2022 classifications on secondary acute myeloid leukemia: Assessing the true qualification power of diagnostic qualifiers. Blood. 2023;142(Supplement 1):819. DOI: 10.1182/blood-2023-185709
- Almeida A, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1-7. DOI: 10.1016/j.lrr.2016.06.001
More about...
Your opinion matters
10 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox